Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|June 22, 2015
Abiraterone With Low-Dose Prednisone in Patients With Prostate Cancer
Author(s)Joseph F. Renzulli, II, MD, FACS
Joseph F. Renzulli, II, MD, FACS, assistant professor of Surgery, (Urology), Alpert Medical School, Brown University, discusses a phase II study that examined the use of abiraterone acetate with low-dose prednisone in patients with prostate cancer.
Advertisement
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
4
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
5